The thioredoxin system has a novel target for treating cancer6, due to these following evidences: both Trx1 and TrxR1 excessively express in a variety of human cancers; overexpressions of Trx1 and Trx2 are significantly associated with more rapid tumor growth, drug resistance and poorer prognosis1,2,3. This evidence concerns the gene TXN and cancer.